NetworkNewsBreaks Archive - Page 2159 of 2221

WednesdayMar 08, 2017 11:44 am

NetworkNewsBreaks – Innovus Pharma (INNV) Receives Notification to Commercialize Sensum+® in the EU; Shares Surge

Shares of Innovus Pharmaceuticals (OTCQB: INNV) are 41% higher mid-morning after the company said it has received the CPNP notification number required to commercialize Sensum+® in all 28 member countries of the European Union. Sensum+® is currently approved to be marketed and sold in 31 countries worldwide, including the United States, Europe, India and Morocco. The company also recently received the CPNP notification number to commercialize Zestra® in the EU on March 2, 2017. “Now that we have received the CPNP notification numbers for Sensum+® and for Zestra®, which we announced last week, Innovus has two products ready to be…

WednesdayMar 08, 2017 10:38 am

NetworkNewsBreaks – ParkerVision, Inc. (NASDAQ: PRKR) Shares Climb on Favorable Decision by PTAB in Final Qualcomm (NASDAQ: QCOM) IPR

Shares of ParkerVision, Inc. (NASDAQ: PRKR) are up 33% this morning on news the Patent Trial and Appeal Board (PTAB) has issued its latest favorable decision for the company in regard to the petitions for Inter Partes Review (IPR) filed by Qualcomm (NASDAQ: QCOM) against ParkerVision patents. Today’s news increases the favorable decisions for the company to over six out of the ten petitions originally filed. There are no further IPR’s challenging ParkerVision patents currently before the PTAB. “We continue to take positive steps forward in our Qualcomm proceedings and believe these results are indicative of the strength of ParkerVision’s…

WednesdayMar 08, 2017 10:36 am

NetworkNewsBreaks – Heron Therapeutics, Inc. (NASDAQ: HRTX) Reiterated with ‘Buy’ Rating at Aegis Capital, PT Adjusted to $33

Aegis Capital has issued a 'Buy' rating and price target of $33 on shares of Heron Therapeutics, Inc.’s (NASDAQ: HRTX) stock. The biotech company most recently announced the inclusion of SUSTOL® as part of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Antiemesis Version 1.2017. FDA-approved SUSTOL was given the highest recommendation of evidence and consensus for use preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving HEC or MEC regimens. “The NCCN is an alliance of 27 leading cancer centers in the US, and this recommendation reaffirms our belief that Sustol extended-released will…

TuesdayMar 07, 2017 3:43 pm

NetworkNewsBreaks – Intellipharmaceutics International (NASDAQ: IPCI) Reiterated with ‘Buy’ Rating, $8 PT at Aegis Capital

Aegis Capital Corp. has reiterated its ‘Buy’ rating and $8 price target on shares of Intellipharmaceutics International (NASDAQ: IPCI). The pharmaceutical company recently received final approval for its abbreviated new drug application for its generic equivalent of the branded product Glucophage® XR. Specifically, the U.S. Food and Drug Administration (FDA) approved metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths. The drug is indicated for use in the management of type 2 diabetes. The company also has eight other abbreviated new drug application candidates awaiting response from the FDA. To view the full press release, visit:…

TuesdayMar 07, 2017 3:42 pm

NetworkNewsBreaks – Concert Pharmaceuticals, Inc.’s (NASDAQ: CNCE) ‘Buy’ Rating, $25 PT Reiterated at Aegis Capital

Aegis Capital Corp. has reiterated a ‘Buy’ rating and $25 price target on the stock of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) following the company’s recent report of financial results for the year ended December 31, 2016. Revenue was $174,000 for the year ended December 31, 2016, compared to $66.7 million for the year ended December 31, 2015. However, because Concert is a clinical-stage company, Aegis cited the events surrounding clinical trials rather than financials. In its earnings release, Concert also announced an asset acquisition agreement in which Vertex Pharmaceuticals will acquire Concert’s CTP-656 for up to $250 million. Concert expects…

TuesdayMar 07, 2017 3:40 pm

NetworkNewsBreaks – Akebia Therapeutics, Inc.’s (NASDAQ: AKBA) ‘Buy’ Rating, $21 PT Reiterated at Aegis Capital

Aegis Capital reiterated its ‘Buy’ rating and $21 price target on shares of Akebia Therapeutics (NASDAQ: AKBA). The biopharmaceutical company recently announced financial results for the fourth quarter and full year ended December 31, 2016, though Aegis focused on the company’s clinical trials and collaboration agreements for the reiteration. As reported in Akebia’s earnings release, full-year 2016 highlights include: the initiation of the global phase 3 INNO2VATE program to evaluate vadadustat in dialysis-dependent patients with anemia associated with chronic kidney disease (CKD); entered into a collaboration with Otsuka Pharmaceutical Co., Ltd in which the companies equally share the costs of…

TuesdayMar 07, 2017 12:22 pm

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Teams with GlobalSim to Launch VR Construction Crane Simulator

Education technology company ProBility Media Corp. (OTCQB: PBYA) this morning announced that it has teamed up with GlobalSim, Inc., a leading provider of simulators and training systems for a variety of industries, to introduce a virtual reality training simulator targeting the crane industry. The two companies have executed an exclusive agreement through which GlobalSim will provide the portable VR Construction Crane hardware and the eLearning software, while ProBility will commercialize the product through its extensive sales channels in both the United States and Canada. “Providing high quality training to the $35 billion crane industry is paramount in our strategy of…

TuesdayMar 07, 2017 11:25 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 7, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MYSZ 34.45% – News: Plans to open a subsidiary in Poland NAKD 17.93% – News: Presenting at the 29th Annual ROTH Conference on March 14 BNKL 17.26% – News: Appoints marketing director GRLD 12.50% – News: Chairman accepts shares of common stock in lieu of salary HPJ 10.20% – News: Posts unaudited Q4, FY 2016 financial results MOSY 6.63% – News: Regains NASDAQ compliance STLT 5.50% – News: Presenting at 29th Annual ROTH Conference…

TuesdayMar 07, 2017 11:25 am

NetworkNewsBreaks – Aeterna Zentaris, Inc. (NASDAQ: AEZS) Receives EMA Pediatric Committee Agreement on PIP for Macrilen™

Shares of Aeterna Zentaris (NASDAQ: AEZS) are 6% higher in morning trade after the company said the European Medicines Agency’s (EMA) Pediatric Committee (PDCO) has agreed to the company’s Pediatric Investigation Plan (PIP) for Macrilen™. PDCO also agreed that Aeterna may defer conducting the PIP until after it files a Marketing Authorization Application (MAA) for the use of Macrilen™ for the evaluation of adult growth hormone deficiency. “PDCO’s agreement that we may defer conducting our PIP, allowing us to go forward with an MAA in adults prior to initiating of the pediatric development program, is an important step forward in…

TuesdayMar 07, 2017 11:22 am

NetworkNewsBreaks – TerraForm Global (NASDAQ: GLBL) Inks Definitive Merger Agreement with Brookfield (NYSE: BAM)

Shares of TerraForm Global, Inc. (NASDAQ: GLBL) are 16% higher after the company announced its definitive merger agreement with Brookfield Asset Management Inc. (NYSE: BAM). Per the agreement, Brookfield will acquire TerraForm Global for approximately $787 million in cash and will assume approximately $455 million in net debt, representing an enterprise value of approximately $1.3 billion. TerraForm Global owns and operates, or has contracts to acquire, a fleet of 31 wind and solar power plants totaling 952 MW of capacity spread across Brazil, India, China, South Africa, Thailand, Malaysia and Uruguay. The transaction is expected to be completed in the…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks